225.63
-2.84 (-1.24%)
| Previous Close | 228.47 |
| Open | 228.16 |
| Volume | 1,566,054 |
| Avg. Volume (3M) | 1,472,546 |
| Market Cap | 38,424,788,992 |
| Price / Earnings (TTM) | 31.04 |
| Price / Earnings (Forward) | 15.60 |
| Price / Sales | 2.50 |
| Price / Book | 6.24 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | 7.88% |
| Operating Margin (TTM) | 13.39% |
| Diluted EPS (TTM) | 6.89 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Quarterly Earnings Growth (YOY) | -26.70% |
| Total Debt/Equity (MRQ) | 272.12% |
| Current Ratio (MRQ) | 0.840 |
| Operating Cash Flow (TTM) | 2.62 B |
| Levered Free Cash Flow (TTM) | 2.45 B |
| Return on Assets (TTM) | 5.16% |
| Return on Equity (TTM) | 19.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | IQVIA Holdings, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.75 |
|
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 1.05% |
| % Held by Institutions | 98.21% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 265.00 (Truist Securities, 17.45%) | Buy |
| 265.00 (Morgan Stanley, 17.45%) | Buy | |
| Median | 250.00 (10.80%) | |
| Low | 200.00 (Barclays, -11.36%) | Hold |
| Average | 242.46 (7.46%) | |
| Total | 10 Buy, 3 Hold | |
| Avg. Price @ Call | 212.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 02 Dec 2025 | 265.00 (17.45%) | Buy | 225.63 |
| BMO Capital | 13 Nov 2025 | 260.00 (15.23%) | Buy | 223.55 |
| TD Cowen | 03 Nov 2025 | 215.00 (-4.71%) | Hold | 213.88 |
| Baird | 29 Oct 2025 | 258.00 (14.35%) | Buy | 217.83 |
| Citigroup | 29 Oct 2025 | 230.00 (1.94%) | Hold | 217.83 |
| JP Morgan | 29 Oct 2025 | 255.00 (13.02%) | Buy | 217.83 |
| Stifel | 29 Oct 2025 | 254.00 (12.57%) | Buy | 217.83 |
| Truist Securities | 29 Oct 2025 | 265.00 (17.45%) | Buy | 217.83 |
| UBS | 29 Oct 2025 | 250.00 (10.80%) | Buy | 217.83 |
| HSBC | 09 Oct 2025 | 235.00 (4.15%) | Buy | 203.00 |
| Evercore ISI Group | 08 Oct 2025 | 240.00 (6.37%) | Buy | 200.60 |
| Barclays | 02 Oct 2025 | 200.00 (-11.36%) | Hold | 204.34 |
| Jefferies | 09 Sep 2025 | 225.00 (-0.28%) | Buy | 189.64 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Dec 2025 | Announcement | IQVIA Announces Strategic Collaboration with AWS, Naming AWS as Preferred Agentic Cloud Provider to Power Next-Generation AI Platform |
| 05 Nov 2025 | Announcement | Dr. William G. Kaelin Jr. joins IQVIA Board of Directors |
| 28 Oct 2025 | Announcement | IQVIA Reports Third-Quarter 2025 Results |
| 21 Oct 2025 | Announcement | IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025 |
| 30 Sep 2025 | Announcement | IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025 |
| 16 Sep 2025 | Announcement | IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships |
| 10 Sep 2025 | Announcement | IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |